D L Carlson Investment Group Inc. Sells 303 Shares of Repligen Co. (NASDAQ:RGEN)

D L Carlson Investment Group Inc. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,787 shares of the biotechnology company’s stock after selling 303 shares during the quarter. D L Carlson Investment Group Inc.’s holdings in Repligen were worth $833,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after buying an additional 56,723 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after acquiring an additional 6,872 shares in the last quarter. DF Dent & Co. Inc. increased its stake in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. New York State Common Retirement Fund raised its position in Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after purchasing an additional 14,398 shares during the period. Finally, Stephens Investment Management Group LLC lifted its stake in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after purchasing an additional 37,057 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN stock opened at $133.41 on Monday. The firm has a 50-day simple moving average of $154.21 and a two-hundred day simple moving average of $148.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a one year low of $113.50 and a one year high of $184.98. The firm has a market cap of $7.49 billion, a price-to-earnings ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on RGEN. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.